Health Care & Life Sciences » Pharmaceuticals | Affimed Therapeutics

Affimed Therapeutics B.V. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
6,753.60
4,486.00
8,385.70
6,984.50
2,267.10
28,001.40
Cost of Goods Sold (COGS) incl. D&A
566.90
-
-
-
-
-
Gross Income
6,186.70
-
-
-
-
-
SG&A Expense
27,844.10
15,254.10
32,402.70
42,183.70
32,850.00
52,360.80
EBIT
21,657.40
11,353.00
24,389.60
35,607.40
30,978.70
24,834.90
Unusual Expense
7,372.30
14,496.70
-
-
-
-
Non Operating Income/Expense
809.90
1,972.40
2,725.70
927.00
2,442.00
2,851.50
Interest Expense
6,442.90
5,679.80
779.60
1,156.00
778.30
999.20
Pretax Income
34,650.80
563.70
22,443.40
35,701.40
34,112.10
22,976.80
Income Tax
1.30
220.20
-
64.20
22.60
1.20
Consolidated Net Income
34,649.50
343.50
22,443.40
35,637.30
34,089.60
22,978
Net Income
34,649.50
343.50
22,443.40
35,637.30
34,089.60
22,978
Net Income After Extraordinaries
34,649.50
343.50
22,443.40
35,637.30
34,089.60
22,978
Net Income Available to Common
34,649.50
343.50
22,443.40
35,637.30
34,089.60
22,978
EPS (Basic)
547.19
0.01
0.79
1.07
0.78
0.38
Basic Shares Outstanding
28,984.20
17,632.80
28,477.40
33,259.50
43,746.10
60,514.40
EPS (Diluted)
1.20
0.02
0.79
1.07
0.78
0.38
Diluted Shares Outstanding
28,984.20
17,632.80
28,477.40
33,259.50
43,746.10
60,514.40
EBITDA
21,090.50
10,768.10
24,017.00
35,199.20
30,582.80
24,359.50
Non-Operating Interest Income
11.90
-
-
135.00
86.90
5.90

About Affimed Therapeutics

View Profile
Address
Technologiepark
Heidelberg Baden Wuerttemberg 69120
Germany
Employees -
Website http://www.affimed.com
Updated 07/08/2019
Affimed NV is a clinical stage biopharmaceutical company, which engages in discovering and developing highly targeted cancer immunotherapies. The company has three proprietary platform technologies which includes: NK-cell TandAbs, T-cell TandAbs and Trispecific Abs. The company was founded in 2000 and is headquartered in Heidelberg, Germany.